NURS 5334 Advanced Pharmacology Final Exam
ACTUAL EXAM 2026/2027 | Complete Exam-
Style Questions | Verified Q&A | Pass
Guaranteed - A+ Graded
Content Area Overview
This actual examination reflects the advanced pharmacological knowledge required for success on the
NURS 5334 Advanced Pharmacology Final Exam. It is designed to evaluate the student's understanding
of pharmacokinetic and pharmacodynamic principles, autonomic nervous system pharmacology,
cardiovascular and renal drug therapy, central nervous system agents, endocrine pharmacology, and
evidence-based prescribing practices. Questions are structured to assess recall of drug classifications
and mechanisms, application of pharmacological principles to clinical scenarios, and analysis of complex
prescribing decisions. This authentic question bank represents the real exams used in the course and
serves as a comprehensive resource for students demonstrating mastery of advanced pharmacology
content for graduate-level Nurse Practitioner practice.
SECTION 1: Pharmacokinetics and Pharmacodynamics
(Questions 1–8)
Question 1
A 68-year-old patient with liver cirrhosis is prescribed a medication that undergoes extensive first-pass
metabolism. The nurse practitioner recognizes that first-pass metabolism primarily occurs in which
organ?
A. Small intestine
B. Liver
C. Kidneys
D. Lungs
B. Liver [CORRECT]
,The best answer is the liver. First-pass metabolism refers to the biotransformation of a drug as it passes
through the hepatic portal system after oral absorption, before reaching systemic circulation. This
significantly reduces bioavailability for many drugs, and in patients with cirrhosis, this process is
impaired—meaning drugs with high first-pass extraction may have unexpectedly higher plasma levels.
This aligns with advanced pharmacology principles regarding hepatic metabolism and its clinical
implications in patients with liver dysfunction.
Correct Answer: B
Question 2
A patient asks why their warfarin dose needs to be adjusted after starting amiodarone. The nurse
practitioner explains that this interaction occurs primarily because amiodarone inhibits which
cytochrome P450 enzyme responsible for warfarin metabolism?
A. CYP2D6
B. CYP3A4
C. CYP2C9
D. CYP1A2
C. CYP2C9 [CORRECT]
This choice is correct because warfarin, particularly the more potent S-warfarin enantiomer, is
metabolized primarily by CYP2C9. Amiodarone is a potent inhibitor of this enzyme, which slows warfarin
clearance and increases INR—sometimes dramatically. When prescribing these together, clinicians
should anticipate a 30–50% reduction in warfarin dose and monitor INR closely. This matches the
mechanism of action for CYP450-mediated drug interactions taught in advanced pharmacology.
Correct Answer: C
Question 3
A 55-year-old male with heart failure is started on digoxin 0.25 mg daily. His serum creatinine is 2.1
mg/dL (eGFR 32 mL/min). The nurse practitioner calculates that digoxin half-life will be prolonged in this
patient primarily due to which pharmacokinetic change?
A. Decreased volume of distribution
B. Reduced renal excretion of unchanged drug
C. Increased hepatic metabolism
D. Enhanced protein binding
B. Reduced renal excretion of unchanged drug [CORRECT]
, The best answer is reduced renal excretion of unchanged drug. Digoxin is eliminated primarily by the
kidneys as unchanged drug—about 60–80% in patients with normal renal function. When GFR drops,
clearance falls proportionally, and half-life extends from the normal 36 hours to 4–5 days or longer in
severe renal impairment. This is why loading doses may be used, but maintenance doses must be
reduced by 25–50% and levels monitored. This aligns with advanced pharmacology principles for dosing
in renal dysfunction.
Correct Answer: B
Question 4
A patient on phenytoin for seizure control has subtherapeutic drug levels despite good adherence. The
nurse practitioner discovers the patient recently started taking sucralfate for GERD. This interaction is
best explained by which mechanism?
A. Sucralfate induces CYP2C9, increasing phenytoin metabolism
B. Sucralfate binds phenytoin in the GI tract, reducing absorption
C. Sucralfate displaces phenytoin from albumin, increasing free drug clearance
D. Sucralfate inhibits renal tubular secretion of phenytoin
B. Sucralfate binds phenytoin in the GI tract, reducing absorption [CORRECT]
This choice is correct because sucralfate is an aluminum salt that forms a protective gel coating in the
stomach, but it also chelates and binds many drugs—including phenytoin, fluoroquinolones, and thyroid
hormone—in the GI lumen. This physically prevents absorption rather than affecting metabolism or
protein binding. The practical teaching point is to separate phenytoin and sucralfate doses by at least 2
hours. This matches the mechanism of action for absorption-related drug interactions.
Correct Answer: B
Question 5
A 42-year-old woman with bipolar disorder is prescribed lithium carbonate. She develops tremor, ataxia,
and confusion. Her lithium level is 2.8 mEq/L (therapeutic range 0.6–1.2). The nurse practitioner
recognizes that lithium has a narrow therapeutic index. Which statement best describes the clinical
significance of a narrow therapeutic index?
A. The drug requires loading doses to reach steady state quickly
B. Small changes in plasma concentration can produce toxicity or therapeutic failure
C. The drug is safe to use in patients with renal impairment
D. The therapeutic effect occurs at doses below the toxic dose
ACTUAL EXAM 2026/2027 | Complete Exam-
Style Questions | Verified Q&A | Pass
Guaranteed - A+ Graded
Content Area Overview
This actual examination reflects the advanced pharmacological knowledge required for success on the
NURS 5334 Advanced Pharmacology Final Exam. It is designed to evaluate the student's understanding
of pharmacokinetic and pharmacodynamic principles, autonomic nervous system pharmacology,
cardiovascular and renal drug therapy, central nervous system agents, endocrine pharmacology, and
evidence-based prescribing practices. Questions are structured to assess recall of drug classifications
and mechanisms, application of pharmacological principles to clinical scenarios, and analysis of complex
prescribing decisions. This authentic question bank represents the real exams used in the course and
serves as a comprehensive resource for students demonstrating mastery of advanced pharmacology
content for graduate-level Nurse Practitioner practice.
SECTION 1: Pharmacokinetics and Pharmacodynamics
(Questions 1–8)
Question 1
A 68-year-old patient with liver cirrhosis is prescribed a medication that undergoes extensive first-pass
metabolism. The nurse practitioner recognizes that first-pass metabolism primarily occurs in which
organ?
A. Small intestine
B. Liver
C. Kidneys
D. Lungs
B. Liver [CORRECT]
,The best answer is the liver. First-pass metabolism refers to the biotransformation of a drug as it passes
through the hepatic portal system after oral absorption, before reaching systemic circulation. This
significantly reduces bioavailability for many drugs, and in patients with cirrhosis, this process is
impaired—meaning drugs with high first-pass extraction may have unexpectedly higher plasma levels.
This aligns with advanced pharmacology principles regarding hepatic metabolism and its clinical
implications in patients with liver dysfunction.
Correct Answer: B
Question 2
A patient asks why their warfarin dose needs to be adjusted after starting amiodarone. The nurse
practitioner explains that this interaction occurs primarily because amiodarone inhibits which
cytochrome P450 enzyme responsible for warfarin metabolism?
A. CYP2D6
B. CYP3A4
C. CYP2C9
D. CYP1A2
C. CYP2C9 [CORRECT]
This choice is correct because warfarin, particularly the more potent S-warfarin enantiomer, is
metabolized primarily by CYP2C9. Amiodarone is a potent inhibitor of this enzyme, which slows warfarin
clearance and increases INR—sometimes dramatically. When prescribing these together, clinicians
should anticipate a 30–50% reduction in warfarin dose and monitor INR closely. This matches the
mechanism of action for CYP450-mediated drug interactions taught in advanced pharmacology.
Correct Answer: C
Question 3
A 55-year-old male with heart failure is started on digoxin 0.25 mg daily. His serum creatinine is 2.1
mg/dL (eGFR 32 mL/min). The nurse practitioner calculates that digoxin half-life will be prolonged in this
patient primarily due to which pharmacokinetic change?
A. Decreased volume of distribution
B. Reduced renal excretion of unchanged drug
C. Increased hepatic metabolism
D. Enhanced protein binding
B. Reduced renal excretion of unchanged drug [CORRECT]
, The best answer is reduced renal excretion of unchanged drug. Digoxin is eliminated primarily by the
kidneys as unchanged drug—about 60–80% in patients with normal renal function. When GFR drops,
clearance falls proportionally, and half-life extends from the normal 36 hours to 4–5 days or longer in
severe renal impairment. This is why loading doses may be used, but maintenance doses must be
reduced by 25–50% and levels monitored. This aligns with advanced pharmacology principles for dosing
in renal dysfunction.
Correct Answer: B
Question 4
A patient on phenytoin for seizure control has subtherapeutic drug levels despite good adherence. The
nurse practitioner discovers the patient recently started taking sucralfate for GERD. This interaction is
best explained by which mechanism?
A. Sucralfate induces CYP2C9, increasing phenytoin metabolism
B. Sucralfate binds phenytoin in the GI tract, reducing absorption
C. Sucralfate displaces phenytoin from albumin, increasing free drug clearance
D. Sucralfate inhibits renal tubular secretion of phenytoin
B. Sucralfate binds phenytoin in the GI tract, reducing absorption [CORRECT]
This choice is correct because sucralfate is an aluminum salt that forms a protective gel coating in the
stomach, but it also chelates and binds many drugs—including phenytoin, fluoroquinolones, and thyroid
hormone—in the GI lumen. This physically prevents absorption rather than affecting metabolism or
protein binding. The practical teaching point is to separate phenytoin and sucralfate doses by at least 2
hours. This matches the mechanism of action for absorption-related drug interactions.
Correct Answer: B
Question 5
A 42-year-old woman with bipolar disorder is prescribed lithium carbonate. She develops tremor, ataxia,
and confusion. Her lithium level is 2.8 mEq/L (therapeutic range 0.6–1.2). The nurse practitioner
recognizes that lithium has a narrow therapeutic index. Which statement best describes the clinical
significance of a narrow therapeutic index?
A. The drug requires loading doses to reach steady state quickly
B. Small changes in plasma concentration can produce toxicity or therapeutic failure
C. The drug is safe to use in patients with renal impairment
D. The therapeutic effect occurs at doses below the toxic dose
